Literature DB >> 23619992

A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity.

Ede Frecska1, Attila Szabo, Michael J Winkelman, Luis E Luna, Dennis J McKenna.   

Abstract

N,N-dimethyltryptamine (DMT) is classified as a naturally occurring serotonergic hallucinogen of plant origin. It has also been found in animal tissues and regarded as an endogenous trace amine transmitter. The vast majority of research on DMT has targeted its psychotropic/psychedelic properties with less focus on its effects beyond the nervous system. The recent discovery that DMT is an endogenous ligand of the sigma-1 receptor may shed light on yet undiscovered physiological mechanisms of DMT activity and reveal some of its putative biological functions. A three-step active uptake process of DMT from peripheral sources to neurons underscores a presumed physiological significance of this endogenous hallucinogen. In this paper, we overview the literature on the effects of sigma-1 receptor ligands on cellular bioenergetics, the role of serotonin, and serotoninergic analogues in immunoregulation and the data regarding gene expression of the DMT synthesizing enzyme indolethylamine-N-methyltransferase in carcinogenesis. We conclude that the function of DMT may extend central nervous activity and involve a more universal role in cellular protective mechanisms. Suggestions are offered for future directions of indole alkaloid research in the general medical field. We provide converging evidence that while DMT is a substance which produces powerful psychedelic experiences, it is better understood not as a hallucinogenic drug of abuse, but rather an agent of significant adaptive mechanisms that can also serve as a promising tool in the development of future medical therapies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23619992     DOI: 10.1007/s00702-013-1024-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  88 in total

1.  The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke.

Authors:  Karsten Ruscher; Mehrdad Shamloo; Mattias Rickhag; Istvan Ladunga; Liza Soriano; Lennart Gisselsson; Håkan Toresson; Lily Ruslim-Litrus; Donna Oksenberg; Roman Urfer; Barbro B Johansson; Karoly Nikolich; Tadeusz Wieloch
Journal:  Brain       Date:  2011-01-28       Impact factor: 13.501

2.  Indolethylamine-N-methyltransferase in developing rabbit lung.

Authors:  R L Lin; S Sargeant; N Narasimhachari
Journal:  Dev Psychobiol       Date:  1974-09       Impact factor: 3.038

3.  Determination and physiological disposition of dimethyltryptamine and diethyltryptamine in rat brain, liver and plasma.

Authors:  I Cohen; W H Vogel
Journal:  Biochem Pharmacol       Date:  1972-04-15       Impact factor: 5.858

4.  Rabbit serum monoamine oxidase. II. Determinants of substrate specificity.

Authors:  C M McEwen; A J Sober
Journal:  J Biol Chem       Date:  1967-07-10       Impact factor: 5.157

Review 5.  Sigma receptor ligands: applications in inflammation and oncology.

Authors:  Bernard Bourrie; Estelle Bribes; Jean-Marie Derocq; Hubert Vidal; Pierre Casellas
Journal:  Curr Opin Investig Drugs       Date:  2004-11

Review 6.  Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways.

Authors:  M Caraglia; M Marra; P Tagliaferri; S W J Lamberts; S Zappavigna; G Misso; F Cavagnini; G Facchini; A Abbruzzese; L J Hofland; G Vitale
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

7.  Agonist properties of N,N-dimethyltryptamine at serotonin 5-HT2A and 5-HT2C receptors.

Authors:  R L Smith; H Canton; R J Barrett; E Sanders-Bush
Journal:  Pharmacol Biochem Behav       Date:  1998-11       Impact factor: 3.533

8.  Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans.

Authors:  R J Strassman; C R Qualls; L M Berg
Journal:  Biol Psychiatry       Date:  1996-05-01       Impact factor: 13.382

9.  Sigma-1 receptor stimulation attenuates calcium influx through activated L-type Voltage Gated Calcium Channels in purified retinal ganglion cells.

Authors:  Brett H Mueller; Yong Park; Donald R Daudt; Hai-Ying Ma; Irina Akopova; Dorota L Stankowska; Abbot F Clark; Thomas Yorio
Journal:  Exp Eye Res       Date:  2012-11-23       Impact factor: 3.467

Review 10.  Interferon lambda: a new sword in cancer immunotherapy.

Authors:  Ahmed Lasfar; Walid Abushahba; Murugabaskar Balan; Karine A Cohen-Solal
Journal:  Clin Dev Immunol       Date:  2011-12-06
View more
  27 in total

Review 1.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

2.  Characterization of pulmonary sigma receptors by radioligand binding.

Authors:  John R Lever; Tyler P Litton; Emily A Fergason-Cantrell
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

Review 3.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 4.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

Review 5.  N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine.

Authors:  Edward James; Joachim Keppler; Thomas L Robertshaw; Ben Sessa
Journal:  Hum Psychopharmacol       Date:  2022-02-17       Impact factor: 2.130

Review 6.  Neuropharmacology of N,N-dimethyltryptamine.

Authors:  Theresa M Carbonaro; Michael B Gatch
Journal:  Brain Res Bull       Date:  2016-04-25       Impact factor: 4.077

7.  Acute Biphasic Effects of Ayahuasca.

Authors:  Eduardo Ekman Schenberg; João Felipe Morel Alexandre; Renato Filev; Andre Mascioli Cravo; João Ricardo Sato; Suresh D Muthukumaraswamy; Maurício Yonamine; Marian Waguespack; Izabela Lomnicka; Steven A Barker; Dartiu Xavier da Silveira
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

Review 8.  Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities.

Authors:  Attila Szabo
Journal:  Front Immunol       Date:  2015-07-14       Impact factor: 7.561

9.  Noncompetitive inhibition of indolethylamine-N-methyltransferase by N,N-dimethyltryptamine and N,N-dimethylaminopropyltryptamine.

Authors:  Uyen B Chu; Sevahn K Vorperian; Kenneth Satyshur; Kelsey Eickstaedt; Nicholas V Cozzi; Timur Mavlyutov; Abdol R Hajipour; Arnold E Ruoho
Journal:  Biochemistry       Date:  2014-04-28       Impact factor: 3.162

10.  Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.

Authors:  Attila Szabo; Attila Kovacs; Ede Frecska; Eva Rajnavolgyi
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.